Everything below concerns Reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-29. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Gender incongruence is marked and sustained Patient meets diagnostic criteria for gender incongruence prior to gender-affirming hormone treatment in regions where a diagnosis is necessary to access health care Patient has capacity to consent to hormone therapy treatment Other possible causes of apparent gender incongruence have been identified and excluded Mental health and physical conditions that could negatively impact the outcome of treatment have been assessed Understands the effect of gender-affirming hormone treatment on reproduction and they have explored reproductive options The WPATH standards of care distinguish between gender-affirming hormone therapy, and hormone replacement therapy, with the latter referring to the replacement of endogenous hormones after a gonadectomy to prevent cardiovascular and musculoskeletal issues.
== Release == The film premiered at the 62nd Cannes Film Festival on 18 May 2009, and went on to screen at festivals such as the Toronto International Film Festival and the Maryland Film Festival. It was released in Greece on 11 November 2009 by Feelgood Entertainment. Verve Pictures acquired distribution rights for the United Kingdom and released it on 23 April 2010. Kino International released it in the United States on 25 June 2010.
Bonny Light oil was found at Oloibiri in the Niger delta region of Nigeria in 1956 for its commercial use. Due to its features of generating high profit, it is highly demanded by refiners. Bonny light oil has an API of 32.9, classified as light oil. It is regarded as more valuable than the other oils with lower API as more high-value products are produced in the refinement. However, in Nigeria, problems due to oil spillage caused by vandalism affect both humans and the ecosystem in detrimental ways. Some experiments on animals and soil are done to figure out those impacts on organisms.
=== Development === On September 30, 2024, FX gave the project an 11-episode series order. The series is based on The Beauty, a creator-owned comic book written by Jeremy Haun and Jason A. Hurley and published by Image Comics. The original comic follows two detectives investigating a sexually transmitted disease that makes those infected physically beautiful but ultimately proves fatal due to side effects. Mac Quayle, a frequent collaborator with Murphy, composed the score for the series.
== M == macroevolution - macromolecular system - macromolecule - macrophage colony-stimulating factor - major histocompatibility complex - Malpighi body - Malpighi layer - marine biology - maslinic acid - mass spectrometer - maturation-promoting factor - mechanoreceptor - medicine - meiosis - melting point - membrane glycoprotein - membrane protein - membrane topology - membrane transport - memory B cell - memory T cell - Mendelian inheritance - metabolic pathway - metabolism - metabotropic glutamate receptor - metalloprotein - metaphase - metazoa - methionine - micelle - Michaelis-Menten kinetics - microbe - microbiology - microevolution - microfilament - microfilament protein - microsatellite - microscope - microtiter plate - microtubule-associated protein - mineralocorticoid receptor - minisatellite - mitochondrial membrane - mitochondrion - mitogen receptor - mitosis - mitotic spindle - mixture - modern evolutionary synthesis - molar volume - mole (unit) - molecular biology - molecular chaperone - molecular dynamics - molecular engineering - molecular evolution - molecular mechanics - molecular modelling - molecular orbital - molecular phylogeny - molecular sequence data - molecule - monoamine - monoclonal antibody - monomer - monosaccharide - monosaccharide transport protein - morphogenesis - morphogenetic field - mos gene - Mössbauer spectroscopy - MRI - MSH - mu opioid receptor - mu-chain immunoglobulin - mucin - Muller's ratchet - multiresistance - muscarinic receptor - muscle - muscle protein - mutagen - mutation - myc gene - mycology - myelin basic protein - myeloma protein - myosin
Sources: en.wikipedia.org
=== Severe intoxication === As of 2007 there is no known antidote or reversal agent for caffeine intoxication. Treatment of mild caffeine intoxication is directed toward symptom relief; severe intoxication may require peritoneal dialysis, hemodialysis, or hemofiltration. Intralipid infusion therapy is indicated in cases of imminent risk of cardiac arrest in order to scavenge the free serum caffeine.
4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for opioid receptors, acting as an antagonist at the μ-opioid receptor (MOR) and as a partial agonist at the κ-opioid receptor (KOR). The affinities (IC50Tooltip half-maximal inhibitory concentration) of 4-hydroxyatomoxetine were 164 nM for the MOR, 88 nM for the KOR, 1,490 nM for the δ-opioid receptor (DOR), and >5,000 nM for the nociceptin receptor (ORL-1). Atomoxetine itself showed dramatically lower affinities (e.g., 25- to 50-fold). It is not known whether the actions of 4-hydroxyatomoxetine at the opioid receptors leads to CNS-related adverse effects with atomoxetine. Atomoxetine does not alter locomotor activity in rodents, in contrast to stimulants like amphetamine. In addition, atomoxetine does not produce self-administration in monkeys, also in contrast to stimulants like amphetamine. The drug does not produce stimulant-like effects, euphoria, or reinforcing effects in humans, instead increasing negative and unpleasant ratings at the highest assessed doses. Atomoxetine has been found to increase cortisol levels in humans.
=== Economics === In December 2019, the US FDA approved a generic version of apixaban produced jointly by Mylan and Micro Labs. BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies. In September 2021, a Federal Circuit Court upheld the ruling. The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031. In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban. Pfizer reported revenue of US$6.747 billion for Eliquis in 2023. Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521. The pricing is set to take effect in 2026.
=== 2010s: Rise of open-source AI frameworks === Open-source deep learning framework as Torch was released in 2002 and made open-source with Torch7 in 2011, and was later augmented by PyTorch, and TensorFlow. AlexNet was released in 2012. OpenAI was founded in 2015 with a mission to create open-source artificial intelligence that benefited humanity, at least in part to help with recruitment in the early phases of the organization. GPT-1 was released in 2018.
Pulse oximetry is a method used to estimate the percentage of oxygen bound to hemoglobin in the blood. This approximation to SaO2 is designated SpO2 (peripheral oxygen saturation). The pulse oximeter is a small device that clips to the body (typically a finger, an earlobe or an infant's foot) and displays its reading, or transfers it to another device. Oxygenated and deoxygenated hemoglobin differ in absorption of light of different wavelengths. The oximeter uses light-emitting diodes of different wavelengths in conjunction with a light-sensitive sensor to measure the absorption of red and infrared wavelengths in the extremity, and estimates the SpO2 from the absorption spectrum.
Sources: en.wikipedia.org
In mass spectrometry, fragmentation is the dissociation of energetically unstable molecular ions formed from passing the molecules mass spectrum. These reactions are well documented over the decades and fragmentation patterns are useful to determine the molar weight and structural information of unknown molecules. Fragmentation that occurs in tandem mass spectrometry experiments has been a recent focus of research, because this data helps facilitate the identification of molecules.
=== Derivatives === Identified uses for DMPEA includes the following list of agents: 1. Bevantolol. 2. Bisobrin 3. Bometolol 4. Buquiterine 5. Denopamine 6. Dobutamine 7. Dopamine 8. Dopexamine 9. Dramedilol 10. Drotaverine 11. Ecastolol 12. Falipamil 13. Gallopamil 14. Methopholine 15. Mixidine 16. Mefeclorazine 17. Nigellimine [4594-02-9] 18. Nuciferine 19. Papaverine 20. Tetrabenazine 21. Tiapamil 22. Trimethoquinol 23. Veradoline 24. Verapamil.
== Prognosis == Individuals with BED often have a lower overall quality of life and face social difficulties. Early behavior changes can predict a full recovery for the future. Individuals who have BED commonly have other conditions such as depression, personality disorder, bipolar disorder, substance abuse, body dysmorphic disorder, kleptomania, irritable bowel syndrome, fibromyalgia, or an anxiety disorder. They may also have history of attempted suicide and reoccurring panic attacks. While people of a normal weight may overeat occasionally, an ongoing habit of consuming large amounts of food in a short period of time may ultimately lead to weight gain and obesity. The main physical health consequences of this type of eating disorder are brought on by the weight gain resulting from calorie-laden bingeing episodes. Mental and emotional consequences of binge eating disorder include social weight stigma and emotional loss of control. Up to 70% of individuals with BED may also be obese, and therefore obesity-associated morbidities such as high blood pressure and coronary artery disease, type 2 diabetes mellitus, gastrointestinal issues (e.g., gallbladder disease), high cholesterol levels, musculoskeletal problems and obstructive sleep apnea may also be present. One study found a 42% obesity rate in those who have received a BED diagnosis. Additionally, a higher morbid obesity prevalence was observed in this population compared to a population without eating disorders.
== Examples == Two-dimensional separations can be carried out in gas chromatography or liquid chromatography. Various different coupling strategies have been developed to "resample" from the first column into the second. Some important hardware for two-dimensional separations are Deans' switch and Modulator, which selectively transfer the first dimension eluent to second dimension column. The chief advantage of two-dimensional techniques is that they offer a large increase in peak capacity, without requiring extremely efficient separations in either column. (For instance, if the first column offers a peak capacity (k1)of 100 for a 10-minute separation, and the second column offers a peak capacity of 5 (k2) in a 5-second separation, then the combined peak capacity may approach k1 × k2=500, with the total separation time still ~ 10 minutes). 2D separations have been applied to the analysis of gasoline and other petroleum mixtures, and more recently to protein mixtures.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.